Matthew Galsky, MD

The data continue to support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial carcinoma.

Matthew D. Galsky, MD, discusses how urologists should approach patient selection for perioperative durvalumab plus chemotherapy based on eligibility criteria for the NIAGARA trial.

"This is another tool in our armamentarium to treat muscle-invasive bladder cancer and represents an advance compared to where we've been over the past few decades," says Matthew D. Galsky, MD.

Types of patients with muscle invasive bladder cancer who may be candidates for a watch-and-wait approach.

Types of educational resources available to support patients with bladder cancer as recommended by urologists and medical oncologists.

Recent trial demonstrates an improvement in outcomes with an adjuvant immune checkpoint inhibitor in urothelial cancer.

Systemic and intravesical therapies are changing the landscape of BCG-unresponsive disease, according to Matthew Galsky, MD.